Takeda to Buy Ariad in $5.2B Move to Build Up Cancer Drug Portfolio

From Xconomy VC, Deals, & Startups
January 9, 2017 - 10:33am
Ariad Pharmaceuticals has agreed to be acquired by Takeda Pharmaceutical in a deal that values the Cambridge, MA-based cancer drug developer at about $5.2 billion. Under the all-cash agreement, Osaka, Japan-based Takeda will acquire all of Ariad’s (NASDAQ: ARIA) outstanding shares for $24 each, a nearly 75 percent premium over the company’s closing stock price […]

Continue reading this article »